Hutchison MediPharma (HMP) is an innovative biopharmaceutical company based in China and the Innovation platform of its parent company, Hutchison China MediTech Limited (HCM). Established in 2002, HMP is aiming to become a global leader in the discovery, development and commercialization of targeted therapies for oncology and immunological diseases.
HMP, has a large scale and fully-integrated in-house research and development (R&D) team of over 350 scientists and staff, which has developed and progressed a broad pipeline of novel oral drug candidates for cancer and inflammation.
HMP’s R&D team use a chemistry-focused approach to develop highly selective small molecule tyrosine kinase inhibitors that are intended to have global first-in-class efficacy or be sufficiently differentiated to be global best-in-class, next generation therapies with a superior profile compared to existing approved drugs that act against the relevant kinase targets. These novel oral compounds for cancer and inflammation are currently in development in North America, Europe, Australia and Greater China and are deliberately engineered to improve drug exposure and reduce known class-related toxicities.
Our strategic partnerships have involved global, innovative companies such as AstraZeneca, Johnson & Johnson, Eli Lilly, Merck Serono and Nestlé Health Science in both oncology and inflammation.